Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73


A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis.

Brown TR, Simnad VI.

Int J MS Care. 2016 Jul-Aug;18(4):170-6. doi: 10.7224/1537-2073.2015-035.


In vitro evaluation of the effects of 4-aminopyridine on cytochrome P450 enzymes.

Caggiano A, Blight A.

J Drug Assess. 2013 Mar 26;2(1):106-16. doi: 10.3109/21556660.2013.818544.


Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat.

Caggiano A, Blight A, Parry TJ.

J Drug Assess. 2013 Apr 12;2(1):72-80. doi: 10.3109/21556660.2013.794143.


Fampridine and quality of life in individuals with multiple sclerosis.

Sagawa Y Jr, Magnin E, Paillot L, Moulin T, Decavel P.

Springerplus. 2016 Jul 13;5(1):1070. doi: 10.1186/s40064-016-2776-2.


4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.

Jayabal S, Chang HH, Cullen KE, Watt AJ.

Sci Rep. 2016 Jul 6;6:29489. doi: 10.1038/srep29489.


Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis.

Guo A, Grabner M, Palli SR, Elder J, Sidovar M, Aupperle P, Krieger S.

Clinicoecon Outcomes Res. 2016 May 12;8:177-86. doi: 10.2147/CEOR.S99750.


Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry.

Meador W, Salter AR, Rinker JR 2nd.

Int J MS Care. 2016 May-Jun;18(3):147-53. doi: 10.7224/1537-2073.2015-008.


Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT.

Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. Review.


Fatigue Management in Multiple Sclerosis.

Tur C.

Curr Treat Options Neurol. 2016 Jun;18(6):26. doi: 10.1007/s11940-016-0411-8. Review.


Fully automated open-source lesion mapping of T2-FLAIR images with FSL correlates with clinical disability in MS.

Wetter NC, Hubbard EA, Motl RW, Sutton BP.

Brain Behav. 2016 Jan 28;6(3):e00440. doi: 10.1002/brb3.440.


Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.

Jara M, Aquilina T, Aupperle P, Rabinowicz AL.

Drug Healthc Patient Saf. 2015 Dec 15;7:169-74. doi: 10.2147/DHPS.S97113.


Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.

Fjeldstad C, Suárez G, Klingler M, Henney HR 3rd, Rabinowicz AL, Pardo G.

Int J MS Care. 2015 Nov-Dec;17(6):275-83. doi: 10.7224/1537-2073.2014-036.


Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).

Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, Oschmann P, Muenssinger J.

BMC Neurol. 2015 Sep 24;15:171. doi: 10.1186/s12883-015-0431-0.


Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR 3rd, Blight AR, Carrazana EJ.

Int J MS Care. 2015 May-Jun;17(3):138-45. doi: 10.7224/1537-2073.2014-040.


Longitudinal changes in self-reported walking ability in multiple sclerosis.

Motl RW, Putzki N, Pilutti LA, Cadavid D.

PLoS One. 2015 May 1;10(5):e0125002. doi: 10.1371/journal.pone.0125002.


Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.

Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.

Mult Scler. 2016 Feb;22(2):212-21. doi: 10.1177/1352458515581436.


Ecological validity of walking capacity tests in multiple sclerosis.

Stellmann JP, Neuhaus A, Götze N, Briken S, Lederer C, Schimpl M, Heesen C, Daumer M.

PLoS One. 2015 Apr 16;10(4):e0123822. doi: 10.1371/journal.pone.0123822.

Items per page

Supplemental Content

Support Center